binx health

Sherlock Biosciences and binx health today announced the companies have entered into a strategic partnership to develop the world’s first rapid, point-of-care diagnostic test for COVID-19 leveraging CRISPR technology. ™-based platforms, we hope to serve as part of the solution to addressing the COVID-19 pandemic by making accurate, affordable diagnostics available everywhere they are needed: in the lab, point-of-care locales, low-resource settings and the home. The currently available SherlockTM CRISPR SARS-CoV-2 kit uses the SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) method to program a CRISPR molecule to detect the presence of a specific SARS-CoV-2 genetic signature in specimens collected from patients suspected of COVID-19 by their healthcare provider. In addition, the FDA cleared, binx io system is a highly flexible and easy-to-use, molecular point-of-care platform leveraging patented, multiplex technology to enable central lab equivalent clinical performance in decentralized, near patient locations such as retail pharmacy, urgent care, and the large and evolving category of consumer “super stores,” that are increasingly serving customer health needs.

Who we are binx is improving sexual health and wellness through new delivery methods that prioritize clinical integrity and consumer privacy and convenience. We provide a first of its kind, comprehensive digital program that includes evidence-based sexually transmitted infection (STI) testing, counseling, treatment, and follow up in order to increase screening and reduce infections. Our proprietary desktop, PCR-based, 30-minute, FDA-cleared, point-of-care testing platform and consumer mobile offerings break down screening barriers through discreet patient-tailored and individualized digital approaches that complement traditional brick-and-mortar care. What You Will Do You will work with our cross-functional software and device teams to assess the quality of FDA regulated medical device software that delivers diagnostic results that are clear and actionable.

Binx and UPS Healthcare pair advanced infectious disease testing with superior global logistics to reach populations everywhere, starting in the United Kingdom binx health ltd. Leveraging the binx digital platform and the Company’s decade of experience developing evidence-based, near-patient infectious disease diagnostics, binx and Polar Speed, a specialist UPS Healthcare business in the UK, have partnered together to broaden access to testing for patients where they need it most—from the comfort and security of their own homes. In addition, the FDA cleared, binx io system is a highly flexible and easy-to-use, molecular point-of-care platform leveraging patented, multiplex technology to enable central lab equivalent clinical performance in decentralized, near patient locations such as retail pharmacy, urgent care, and the large and evolving category of consumer “super stores,” that are increasingly serving customer health needs. For parcels requiring strict temperature environments, from CRT to cryogenic, and those requiring around-the-clock monitoring, UPS Healthcare has solutions such as UPS Temperature True® and UPS Proactive Response® services.

The study shows that the binx io provides accurate results in about 30 minutes, enabling single visit test and treatment for chlamydia (CT) and gonorrhea (NG), two of the most tested-for sexually transmitted infections (STIs) globally. The standard of care today for CT/NG testing often requires 2-10 days of delay between sample collection and answer, resulting up to 40% of positive patients not returning for treatment[1]. With CT/NG infections already at record highs—and the broad cessation of routine STI testing related to impacts of COVID-19[2]—the need for the binx io rapid, molecular point-of-care platform is especially acute. Barbara Van Der Pol, MPH, PhD, President of the American Sexually Transmitted Diseases Association and Principal Investigator of the clinical study at the University of Alabama at Birmingham, described the binx io CT/NG assay as “a highly accurate test that allows rapid results to be available during the patient visit. The FDA cleared, binx io system is a highly flexible and easy-to-use, molecular point-of-care platform leveraging patented, multiplex technology to enable central lab equivalent clinical performance in decentralized, near patient locations such as retail pharmacy, urgent care, and the large and evolving category of consumer “super stores,” that are increasingly serving customer health needs.